Home » Topics » Disease categories and therapies » Musculoskeletal

Musculoskeletal
RSS

Vertex patents heterocyclic p38 MAP kinase inhibitors and their use

Jan. 17, 2000

Esteve presents new COX-2 inhibitor and pharmacological profile

Jan. 14, 2000

Vertex continues to pursue therapeutically active p38 MAP kinase inhibitors

Jan. 14, 2000

Further investigations on the antiinflammatory effect of rutaecarpine

Jan. 13, 2000

Alpha4-selective integrin antagonists in the Celltech pipeline

Jan. 12, 2000

Rat adjuvant arthritis ameliorated by thalidomide analogue

Jan. 10, 2000

The antiplatelet agent triflusal now shown to inhibit NF-kappaB activation

Jan. 10, 2000

Orally active, selective iNOS inhibitors discovered at Glaxo Wellcome

Jan. 6, 2000

Imidazole cytokine inhibitors in the pipeline at SmithKline Beecham

Jan. 6, 2000

RWJ-67657 undergoes further study based on favorable preliminary biological profile

Jan. 5, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...